Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.83 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.83 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 3/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.83 |
| ▸ | TP53 | P04637 | 3/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.83 |
| ▸ | MAPT | P10636 | 3/20 | 0.83 |
| ▸ | HPGD | P15428 | 3/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.83 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.83 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.83 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.83 |
| ▸ | CA12 | O43570 | 2/20 | 0.83 |
| ▸ | CA1 | P00915 | 2/20 | 0.83 |
| ▸ | CA2 | P00918 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resveratrol SCHEMBL27716066 | 1.00 | KDM4E (0.83) | KDM4EPTGS1CYP1A1CYP1A2MEN1 | |
| Resveratrol SCHEMBL721421 | 1.00 | KDM4E (0.83) | KDM4EPTGS1CYP1A1CYP1A2MEN1 | |
| Resveratrol SCHEMBL15441562 | 0.96 | KDM4E (0.83) | KDM4EPTGS1CYP1A1CYP1A2MEN1 | |
| Resveratrol SCHEMBL15441560 | 0.96 | KDM4E (0.83) | KDM4EPTGS1CYP1A1CYP1A2MEN1 | |
| Resveratrol SCHEMBL28307179 | 0.96 | KDM4E (0.91) | KDM4EPTGS1CYP1A1CYP1A2MEN1 | |
| Pinosylvin SCHEMBL9419839 | 0.93 | LCK (0.71) | KDM4EPTGS1CYP1A1CYP1A2MEN1 | |
| Pinosylvin SCHEMBL3940383 | 0.93 | LCK (0.71) | KDM4EPTGS1CYP1A1CYP1A2MEN1 | |
| Pinosylvin SCHEMBL7075363 | 0.93 | LCK (0.71) | KDM4EPTGS1CYP1A1CYP1A2MEN1 | |
| Pinosylvin SCHEMBL454262 | 0.93 | LCK (0.71) | KDM4EPTGS1CYP1A1CYP1A2MEN1 | |
| Pinosylvin SCHEMBL20455852 | 0.93 | LCK (0.71) | KDM4EPTGS1CYP1A1CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-9597299-B2 | Method for treating gefitinib-resistant non-small-cell lung cancer | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (MO) | 2017-03-21 | — | — | US | disclosed |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM | 2016-10-06 | — | — | US | disclosed |
| US-20160158163-A1 | Method For Treating Gefitinib-Resistant Non-Small-Cell Lung Cancer | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-06-09 | — | — | US | disclosed |
| WO-2015085143-A2 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20020110604-A1 | Composition exhibiting synergistic antioxidant activity | ASHNI NATURACEUTICALS, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002013835-A1 | COMPOSITION EXHIBITING SYNERGISTIC ANTIOXIDANT ACTIVITY | ASHNI NATURACEUTICALS, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | CUTA, TSLP, ELANE | KDM4E 3199/4885PTGS1 1081/4885CYP1A1 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.